Imaging evaluation of prostate cancer with 18F- fluorodeoxyglucose PET/CT: Utility and limitations

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue SUPPL. 1, 2013, Pages

  Jadvar, Hossein ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cancer; FDG; PET; Prostate

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; DIAGNOSTIC AGENT;

CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HUMAN; METASTASIS; PREDICTION; PRIMARY TUMOR; PROSTATE CANCER; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; MALE; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROSTATE TUMOR; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84886098756     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2361-7     Document Type: Review

References (45)

1. Surveillance Epidemiology and End Results. National Cancer Institute. Stat fact sheets: prostate. Available from: http://seer.cancer.gov/ statfacts/html/prost.html.
2. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61:1079-92.
3. Kessler B, Albertsen P. The natural history of prostate cancer. Urol Clin N Am. 2003;30:219-26.
4. Carroll P. Rising PSA, after a radical treatment. Eur Urol. 2001;40:9-16.
5. Fox JJ, Morris MJ, Larson SM, Schoder H, Scher HI. Developing imaging strategies for castration resistant prostate cancer. Acta Oncol. 2011;50 Suppl 1:39-48.
6. Marques RB, Erkens-Schulze S, de Ridder CM, Hermans KG, Waltering K, Visakorpi T, et al. Androgen receptor modifications in prostate cancer cells upon long-term androgen ablation and antiandrogen treatment. Int J Cancer. 2005;117:221-9.
7. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148-59.
8. Apolo AB, Pandit-Taskar N, Morris MJ. Novel tracers and their development for the imaging of metastatic prostate cancer. J Nucl Med. 2008;49:2031-41.
9. Jadvar H. Molecular imaging of prostate cancer: PET radiotracers. AJR Am J Roentgenol. 2012;199:278-91.
10. Macheda ML, Rogers S, Bets JD. Molecular and cellular regulation of glucose transport (GLUT) proteins in cancer. J Cell Physiol. 2005;202:654-62.
11. Smith TA. Mammalian hexokinases and their abnormal expression in cancer. Br J Biomed Sci. 2000;57:170-8.
12. Effert P, Beniers AJ, Tamimi Y, Handt S, Jakse G. Expression of glucose transporter 1 (GLUT-1) in cell lines and clinical specimen from human prostate adenocarcinoma. Anticancer Res. 2004;24:3057-63.
13. Stewardt GD, Gray K, Pennington CJ, Edwards DR, Riddick AC, Ross JA, et al. Analysis of hypoxia-associated gene expression in prostate cancer: lysyl oxidase and glucose transporter 1 expression correlate with Gleason score. Oncol Rep. 2008;20:1561-7.
14. Jadvar H, Li X, Shahinian A, Park R, Tohme M, Pinski J, et al. Glucose metabolism of human prostate cancer mouse xenografts. Mol Imaging. 2005;4:91-7.
15. 11C-acetate in human prostate cancer cell lines? Eur J Nucl Med Mol Imaging. 2011;38:1842-53.
16. Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med. 1995;36:1625-32.
17. Moon JS, Jin WJ, Kwak JH, Kim HJ, Yun MJ, Kim JW, et al. Androgen stimulates glycolysis for de novo lipid synthesis by increasing activities of hexokinase 2 and 6-phosphofructo-2-kinase/ fructose-2,6-biphosphatase 2 in prostate cancer cells. Biochem J. 2011;433:225-33.
18. Kukuk D, Reischl G, Raguin O, Wiehr S, Judenhofer MS, Calaminus C, et al. Assessment of PET tracer uptake in hormone-independent and hormone-dependent xenograft prostate cancer mouse models. J Nucl Med. 2011;52:1654-63.
19. Salminen E, Hogg A, Binns D, Frydenberg M, Hicks R. Investigations with FDG PET scanning in prostate cancer show limited value for clinical practice. Acta Oncol. 2002;41:425-9.
20. Jadvar H. Molecular imaging of prostate cancer with [F-18]- fluorodeoxyglucose PET. Nat Rev Urol. 2009;6:317-23.
21. Jadvar H, Ye W, Groshen S, Conti PS. [F-18]-fluorodeoxyglucose PET-CT of the normal prostate gland. Ann Nucl Med. 2008;22:787-93.
22. Minamimoto R, Uemura H, Sano F, Terao H, Nagashima Y, Yamanaka S, et al. The potential of FDG PET/CT for detecting prostate cancer in patients with an elevated serum PSA level. Ann Nucl Med. 2011;25:21-7.
23. Minamimoto R, Senda M, Jinnouchi S, Terauchi T, Yoshida T, Murano T, et al. The current status of an FDG-PET cancer screening program in Japan based on a 4-year (2006-2009) nationwide survey. Ann Nucl Med. 2013;27:46-57.
24. 18F-fluorodeoxyglucose PET, and MR imaging. J Magn Reson Imaging. 2010;31:1151-6.
25. Hwang I, Chong A, Jung SI, Hwang EC, Kim SO, Kang TW, et al. Is further evaluation needed for incidental focal uptake in the prostate in 18-fluoro-2-deoxyglucose positron emission tomography-computed tomography images? Ann Nucl Med. 2012. doi:10.1007/s12149-012-0663-7.
26. Hillner BE, Siegel BA, Shields AF, Liu D, Gareen IF, Hunt E, et al. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the National Oncologic PET Registry. J Nucl Med. 2008;49:1928-35.
27. Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology. 2001;57:108-11.
28. Kao PF, Chou YH, Lai CW. Diffuse FDG uptake in acute prostatitis. Clin Nucl Med. 2008;33:308-10.
29. Oyama N, Akino H, Suzuki Y, Kanamaru H, Sadato N, Yonekura Y, et al. The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol. 1999;29:623-9.
30. Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association prostate guidelines for localized prostate cancer update panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177:540-5.
31. Roach III M, Hanks G, Thames Jr H, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOGASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys. 2006;65:965-74.
32. Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C, et al. The role of choline positron emission tomography/computed tomography in the management of patients with prostatespecific antigen progression after radical treatment of prostate cancer. Eur Radiol. 2011;59:51-60.
33. Chang CH, Wu HC, Tsai JJ, Shen YY, Changlai SP, Kao A. Detecting metastatic pelvic lymph nodes by (18)F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer. Urol Int. 2003;70:311-5.
34. Schöder H, Herrmann K, Gönen M, Hricak H, Eberhard S, Scardino P, et al. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for detection of disease in patients with prostatespecific antigen relapse after radical prostatectomy. Clin Cancer Res. 2005;11:4761-9.
35. Seltzer MA, Barbaric Z, Belldegrun A, Naitoh J, Dorey F, Phelps ME, et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol. 1999;162:1322-8.
36. 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med. 2012;37:637-43.
37. Oyama N, Akino H, Suzuki Y, Kanamaru H, Ishida H, Tanase K, et al. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl Med Commun. 2001;22:963-9.
38. Haberkorn U, Bellemann ME, Altmann A, Gerlach L, Morr I, Oberdorfer F, et al. PET 2-fluoro-2-deoxyglucose uptake in rat prostate adenocarcinoma during chemotherapy with gemcitabine. J Nucl Med. 1997;38:1215-21.
39. Jadvar H, Desai B, Quinn D, Dorff T, Pinski J, Conti P, et al. Treatment response assessment of metastatic prostate cancer with FDG PET/CT. J Nucl Med. 2011;52 Suppl 1:1908.
40. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the PSAWorking Group. J Clin Oncol. 1999;17:1-7.
41. Oyama N, Akino H, Suzuki Y, Kanamaru H, Miwa Y, Tsuka H, et al. Prognostic value of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer. Mol Imaging Biol. 2002;4:99-104.
42. Morris MJ, Akhurst T, Larson SM, Ditullio M, Chu E, Siedlecki K, et al. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res. 2005;11:3210-6.
43. Meirelles GS, Schoder H, Ravizzini GC, Gönen M, Fox JJ, Humm J, et al. Prognostic value of baseline [18F]fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing prostate cancer. Clin Cancer Res. 2010;16:6093-9.
44. Imbriaco M, Larson SM, Yeung HW, Mawlawi OR, Erdi Y, Venkatraman ES, et al. A new parameter for measuring metastatic bone involvement by prostate cancer: the bone scan index. Clin Cancer Res. 1998;4:1765-72.
45. Jadvar H, Desai B, Ji L, Conti P, Dorff T, Pinski J, et al. Prognostic utility of FDG PET/CT in men with castrate-resistant metastatic prostate cancer. J Nucl Med. 2012;53 Suppl 1:116.